Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 2/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.42 |
| ▸ | CPA1 | P15085 | 2/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19742368 | 0.86 | CPA3 (0.55) | CPA3FOLH1CYP1A2NAALAD2 | |
| SCHEMBL21314340 | 0.83 | CPA3 (0.52) | CPA3FOLH1CPB2 | |
| SCHEMBL23923864 | 0.79 | CPA3 (0.53) | CPA3FOLH1CYP1A2NAALAD2ALDH1A1 | |
| SCHEMBL29088272 | 0.74 | CPA3 (1.00) | CPA3FOLH1CYP1A2NAALAD2CPA1 | |
| SCHEMBL3963424 | 0.74 | CPA3 (1.00) | CPA3FOLH1CYP1A2NAALAD2CPA1 | |
| SCHEMBL1376183 | 0.73 | CPA3 (0.58) | CPA3FOLH1CYP1A2NAALAD2CPA1 | |
| SCHEMBL7350860 | 0.73 | CPA3 (0.71) | CPA3FOLH1CYP1A2CPA1 | |
| SCHEMBL1377036 | 0.70 | CPA3 (0.54) | CPA3FOLH1CYP1A2NAALAD2 | |
| SCHEMBL17912665 | 0.70 | FOLH1 (0.42) | FOLH1NAALAD2 | |
| SCHEMBL3774843 | 0.69 | CPA3 (0.51) | CPA3FOLH1CYP1A2NAALAD2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170368208-A1 | CANCER IMAGING AGENT | ENDOCYTE INC (US) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368208-A1 | CANCER IMAGING AGENT | TSG101, TP53, VHL | CPA3 1150/4885FOLH1 20/4885CYP1A2 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.